{
    "clinical_study": {
        "@rank": "156395", 
        "arm_group": {
            "arm_group_label": "Askina Calgitrol Paste", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy of Askina\u00ae Calgitrol\u00ae Paste in reducing\n      local infection in subjects treated for mildly infected Diabetic Foot Ulcers (DFU) with\n      Askina\u00ae Calgitrol\u00ae Paste."
        }, 
        "brief_title": "Askina Calgitrol Paste Diabetic Foot Ulcers", 
        "condition": "Diabetic Foot Ulcer (DFU)", 
        "condition_browse": {
            "mesh_term": [
                "Ulcer", 
                "Foot Ulcer", 
                "Diabetic Foot"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject older than 18 years old\n\n          -  Provision of written consent by the subject themselves\n\n          -  Subjects with a Texas stage I-B wound below the malleolus: superficial and infected\n             (Wagner-Armstrong classification system).\n\n          -  Subjects with a mildly infected wound according to the Infectious Diseases Society of\n             America (IDSA).\n\n          -  Size of wound >2 cm2.\n\n          -  Absence of ischaemia of the lower limb as assessed by :\n\n               1. Transcutaneous oxygen pressure (TcPO2) > 30 mmHg.\n\n               2. Toe pressure > 50 mmHg.\n\n               3. Ankle pressure > 70 mmHg.\n\n          -  Capable of following Study instructions.\n\n          -  Compliant with treatment and in particular with off-loading regime.\n\n          -  Stable management of their diabetes as defined by an HbA1C (%) of 12%\n\n        Exclusion Criteria:\n\n          -  Subjects who are <18 years old.\n\n          -  Subjects with a documented sensitivity to alginates or silver.\n\n          -  Subjects taking a medication or using a device comprising silver.\n\n          -  Subjects already taking antibiotics before enrolment\n\n          -  Subjects undergoing dialysis.\n\n          -  Subjects using therapy known to be immune-compromising such as systemic\n             anti-neoplastic drugs and/or systemic cortico-steriods.\n\n          -  Pregnancy\n\n          -  Breast-feeding\n\n          -  Currently participating in another clinical trial, or who have participated in\n             another clinical trial in the last 6 weeks or who have previously taken part in this\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01912092", 
            "org_study_id": "OPM-O-H-1205"
        }, 
        "intervention": {
            "arm_group_label": "Askina Calgitrol Paste", 
            "intervention_name": "Askina Calgitrol paste", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 29, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Giacomo Clerici, Doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Mila", 
                        "country": "Italy"
                    }, 
                    "name": "IRCCS Casa di Cura MultiMedica"
                }, 
                "investigator": {
                    "last_name": "Giacomo Clerici, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Roberto De Giglio, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy"
                    }, 
                    "name": "Diabetic Foot and metabolic diseases clinic"
                }, 
                "investigator": {
                    "last_name": "Roberto De Giglio, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "A NON-CONTROLLED PROSPECTIVE COHORT STUDY OF THE USE OF ASKINA\u00ae CALGITROL\u00ae PASTE + STANDARD OF CARE ON MILDLY INFECTED, NON-ISCHAEMIC DIABETIC FOOT ULCERS", 
        "overall_contact": {
            "email": "ghislaine.martin@bbraun.com", 
            "last_name": "Ghislaine MARTIN, PhD"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "During each of the day 2 and weekly control visits, the investigator will observe the wound visually and assess it for signs of Clinical infection, using the Guidelines for Diabetic Foot Ulcer infection of the Infectious Diseases Society of America. The investigator will score the degree of infection of the wound according to a table adapted from the 8 items wound score for diabetic foot infections.\nIn general, treatment with Askina Calgitrol Paste will be discontinued when local infection has resolved or when it was worsened since the last control visit. However, treatment of Askina Calgitrol Paste will continued after 4 weeks of treatment only if there are signs of improvement.\nThe treatment period of Askina Calgitrol Paste will last a maximum of 6 weeks.", 
            "measure": "Clinical signs of local infection (Presence of erythema, pain, tenderness, warmth or induration)", 
            "safety_issue": "No", 
            "time_frame": "At day 0, day 2 and weekly in a period of a maximum of 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01912092"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Adverse events or Adverse device related event", 
                "safety_issue": "Yes", 
                "time_frame": "At day 2 and weekly in a period of a maximum of 6 weeks"
            }, 
            {
                "description": "It will be assessed visually by the investigator.", 
                "measure": "Evaluation of wound bed (necrosis, slough, granulation, epithelialisation)", 
                "safety_issue": "No", 
                "time_frame": "At day 0, day 2 and weekly in a period of a maximum of 6 weeks"
            }, 
            {
                "description": "Ease of application and removal of dressing will be assessed by the subject/subject's relatives and the investigator using a rating scale of 1 (very easy) to 5 (very difficult). Dressing change at home will be evaluated in a patient diary by the patient or the carer and dressing changes in the clinic by the investigator.", 
                "measure": "Ease of use of Askina Calgitrol Paste", 
                "safety_issue": "No", 
                "time_frame": "Daily or at every change of dressing, in a period of a maximum of 6 weeks"
            }, 
            {
                "description": "It will be measured by Visitrak Wound Measurement System at each clinic visit by the healthcare professional.", 
                "measure": "Wound surface area", 
                "safety_issue": "No", 
                "time_frame": "At day 0, day 2 and weekly in a period of a maximum of 6 weeks"
            }
        ], 
        "source": "BBraun Medical SAS", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BBraun Medical SAS", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}